Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History TNXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics TNXP

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Tonix Pharmaceuticals Holding Corp

TNXP
Current price
38.36 USD +3.02 USD (+8.55%)
Last closed 35.44 USD
ISIN US8902608392
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 261 033 456 USD
Yield for 12 month -38.13 %
1Y
3Y
5Y
10Y
15Y
TNXP
21.11.2021 - 28.11.2021

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey. Address: 26 Main Street, Chatham, NJ, United States, 07928

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

61.67 USD

P/E Ratio

0.100

Dividend Yield

Financials TNXP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures TNXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+10 094 000 USD

Last Year

+7 768 000 USD

Current Quarter

+2 429 000 USD

Last Quarter

+2 582 000 USD

Current Year

+2 329 000 USD

Last Year

+3 027 000 USD

Current Quarter

+1 486 000 USD

Last Quarter

+1 399 000 USD
EBITDA -69 543 000 USD
Operating Margin TTM -660.93 %
Price to Earnings 0.100
Return On Assets TTM -27.59 %
PEG Ratio
Return On Equity TTM -91.44 %
Wall Street Target Price 61.67 USD
Revenue TTM 10 041 000 USD
Book Value 26.23 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -2.10 %
Dividend Yield
Gross Profit TTM 2 993 000 USD
Earnings per share 356.28 USD
Diluted Eps TTM 356.28 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation TNXP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 0.100
Forward PE
Enterprise Value Revenue 12.94
Price Sales TTM 26.00
Enterprise Value EBITDA 0.94
Price Book MRQ 1.45

Technical Indicators TNXP

For 52 Weeks

6.76 USD 83.83 USD
50 Day MA 29.60 USD
Shares Short Prior Month 1 056 374
200 Day MA 22.19 USD
Short Ratio 0.85
Shares Short 1 129 784
Short Percent 15.36 %